

UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY

**IN RE: VALSARTAN LOSARTAN &  
IRBESARTAN PRODUCTS LIABILITY  
LITIGATION**

This Document Relates to All Actions

MDL No. 2875

Case No. 1:19-md-02875

Honorable Robert B. Kugler,  
District Court Judge

Honorable Karen M. Williams,  
Magistrate Judge

**RULE 7.1.1(a) DISCLOSURE STATEMENT**

Defendant, Sciegen Pharmaceuticals, Inc. (“Sciegen”), hereby notifies the Court, pursuant to Local Rule 7.1.1(a), that there is no person or entity not a party to this action providing funding for any portion of Sciegen’s attorney’s fees or expenses of litigation in exchange for (1) a contingent financial interest based upon the results of the litigation; or (2) a nonmonetary result that is not in the nature of a personal or bank loan, or insurance.

Dated: July 28, 2021

Respectfully submitted,

/s/ Geoffrey M. Coan

Geoffrey M. Coan

HINSHAW & CULBERTSON, LLP

53 State Street, 27<sup>th</sup> Floor

Boston, MA 02109

617-213-7000; 617-213-7001 fax

[gcoan@hinshawlaw.com](mailto:gcoan@hinshawlaw.com)

*Attorneys for Sciegen Pharmaceuticals, Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that on July 28, 2021, I electronically filed the foregoing **7.1.1(a) Disclosure Statement** with the Clerk of the Court by using the CM/ECF system which will send a notice of electronic filing to all CM/ECF participants in this matter.

/s/ Geoffrey M. Coan  
Geoffrey M. Coan